TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$145.99 USD
-3.20 (-2.14%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $145.56 -0.43 (-0.29%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.99 USD
-3.20 (-2.14%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $145.56 -0.43 (-0.29%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Zacks News
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -44.44% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 8.00% and 24.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021
by Sriparna Ghosal
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Maxar (MAXR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Maxar's (MAXR) fourth-quarter performance is likely to have benefited from growth in the Imagery and Services segment.
TransMedics' OCS Technology Sees Success in Heart Transplant
by Zacks Equity Research
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.